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Objectives. This report discusses the outcome at 1 year in 
patients in the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. 
Background. Comparative fficacy of medical therapy versus 
revascularization in treatment of asymptomatic ischemia is un- 
known. The ACIP study assessed the ability of three treatment 
strategies to suppress ambulatory electrocardiographic (ECG) 
ischemia to determine whether a large-scale trial studying the 
impact of these strategies on clinical outcomes was feasible. 
Methods. Five hundred fifty-eight patients with coronary anat- 
omy amenable to revascularization, at least one episode of asymp- 
tomatic ischemia on the 48-h ambulatory ECG and ischemia on 
treadmill exercise testing were randomized to one of three treat- 
ment strategies: 1)medication to suppress angina (angina-guided 
strategy, n = 183); 2) medication to suppress both angina and 
ambulatory ECG ischemia (ischemia.guided strategy, n = 183); or 
3) revascularization strategy (angioplasty or bypass urgery, n = 
192). Medication was titrated atenoloi-nifedipine or diltiazem- 
isosorbide dinitrate. 
Results. The revascularization group received less medication 
and had less ischemia on serial ambulatory ECG recordings and 
exercise testing than those assigned to the medical strategies. The 
ischemia-guided group received more medication but had sup- 
pression of ischemia similar to the angina-guided group. At 1 
year, the mortality rate was 4.4% in the angina.guided group (8 of 
183), 1.6% in the ischemia-guided group (3 of 183) and 0% in the 
revascularization group (overall, p = 0.004; angina-guided vs. 
revascularization, p = 0.003; other pairwise comparisons, p = 
NS). Frequency of myocardial infarction, unstable angina, stroke 
and congestive heart failure was not significantly different among 
the three strategies. The revascnlarization group had significantly 
fewer hospital admissions and nonprotocoi revascularizations at 
I year. The incidence of death, myocardial infarction, nonprotocol 
revascularization r hospital admissions at 1 year was 32% with 
the angina-guided medical strategy, 31% with the ischemia-guided 
medical strategy and 18% with the revascularization strategy (p = 
0.003). 
Conclusions. After 1 year, revascularization was superior to 
both angina-guided and ischemia-guided medical strategies in 
suppressing asymptomatic schemia and was associated with 
better outcome. These findings require confirmation by a larger 
scale trial. 
(J Am CoU Cardiol 1995;26:594-605) 
Asymptomatic cardiac ischemia is a common clinical syndrome 
estimated to affect up to 3 million persons in the United States, 
the majority of whom also experience angina (1). Several 
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studies (2-7) have demonstrated higher cardiac morbidity and 
mortality, among patients with coronary artery disease if asymp- 
tomatic ischemia ispresent. Although asymptomatic is hemia can 
be treated with variable success by either pharmacologic therapy 
or revascularization (8-10), the relative tficacy of these modali- 
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ties either to control ischemia detected by ambulatory electrocar- 
diographic (ECG) monitoring or to improve clinical outcome is 
uncertain. 
Accordingly, the National Heart, Lung, and Blood Institute- 
sponsored Asymptomatic Cardiac Ischemia Pilot (ACIP) study 
was undertaken to assess the role of three strategies to 
suppress asymptomatic is hemia nd to ascertain the feasibility 
of a large-scale trial to study the impact of these strategies on 
clinical outcomes, such as death and myocardial infarction 
(11,12). The three strategies tested in the ACIP study were 
1) pharmacologic therapy titrated to alleviate angina; 2) phar- 
macologic therapy titrated to alleviate both angina and 
asymptomatic ischemia, as assessed by ambulatory ECG; and 
3) revascularization byeither percutaneous transluminal cor- 
onary angioplasty or coronary artery bypass graft surgery. At 
12-week follow-up, revascularization was found to be the most 
effective of the three strategies in reducing ischemic episodes, 
but clinical outcome was similar with each strategy (13). 
Because the relative efficacy of the three strategies might 
change with extended follow-up, serial assessment of myocar- 
dial ischemia nd clinical events was continued through 1year 
after randomization. The purpose of the present report is to 
describe outcome at 1 year after entry for patients assigned to 
the three treatment s rategies, to relate 1-year outcome to the 
previously" reported 12-week outcome and to further evaluate 
the need for a large scale interventional trial. 
Methods 
Study design. Details of the ACIP trial design and meth- 
odology have been described previously (1E). Briefly, consent- 
ing patients with arteriographically documented coronary 
artery disease (->50% diameter stenosis) amenable to revas- 
cularization, at least one episode of asymptomatic is hemia on 
a 48-h ambulatory ECG and evidence of ischemia on a 
treadmill exercise test (or pharmaceutical stress perfusion 
study if unable to exercise) were randomized to one of three 
treatment strategies: 1) pharmacologic therapy for angina 
(angina-guided strategy); 2) pharmacologic therapy to sup- 
press both angina and ambulatory ECG evidence of ischemia 
(ischemia-guided strategy); and 3) revascularization with ei- 
ther angioplasty or bypass urgery within 4 weeks of entry, 
according to physician and patient preference (revasculariza- 
tion strategy). Ambulatory ECG evidence of ischemia was 
defined as -> 1-mm ST segment deviation from baseline lasting 
->1 min. Exercise test evidence of ischemia was defined as 
either horizontal or downsloping ST depression ->0.1 mV or 
upsloping ST segment depression -> 1.5 mV at 80 ms after the 
J point. Assignment to angina-guided and ischemia-guided 
strategy was carried out in double-blinded manner. 
Pharmacologic therapy consisted of a titrated regimen of 
atenolol, followed by sustained-release nifedipine if needed, or 
a titrated regimen of diltiazem, followed by sustained-release 
isosorbide dinitrate if needed. The decision to use atenolol- 
nifedipine versus diltiazem-isosorbide initrate was made by 
random assignment for patients eligible to receive either 
Eligible Patients 
( Qualifying AECG, ETT, Coronary Arteriograms) 
I 
Randomization 
I Anoina-GuideO~ Ischemia-Guided~ Revascularizatiqn 
4 wks AECG PTCA or CABG 
8 wks AECG 
12 wks AECG (pdmary endpoint), ETT 
I 
6 mos AECG, ETT 
[ 
12 mos AECG, E-i-I- 
Figure 1. Sequence of testing for ischemia n the ACIP study from 
entry through l-year follow-up. AECG = ambulatory electrocardio- 
gram; CABG = coronary artery bypass graft surgery; ETT = treadmill 
exercise test (or equivalent); PTCA = percutaneous transluminal 
coronary angioplasty. 
regimen and according to physician preference otherwise. 
During the first 4 weeks after randomization, and at any time 
subsequently, open-label medication was used to suppress 
angina. During the next 8 weeks, medication (active drug or 
placebo) was administered in blinded manner, according to 
whether esidual ischemia was found on repeat 48-h ambula- 
tory ECG recordings at 4 and 8 weeks after randomization 
(patients assigned to the angina-guided strategy received pla- 
cebo; patients assigned to the ischemia-guided strategy re- 
ceived active drugs). After the reassessment of ischemia by 
both ambulatory ECG and exercise test at 12 weeks after entry, 
patients were directed to continue their current medical regi- 
men through 1 year after study entry. Ischemia was again 
assessed at the 6-month and 1-year follow-up visits (Fig. 1), but 
the results were not used to alter medication usage. 
Outcome assessment. In the ACIP study the primary out- 
come for comparing the three treatment strategies was the 
complete suppression of ischemic episodes on the 48-h ambu- 
latory ECG obtained at the 12-week visit (84 to 182 days after 
entry). Prespecified secondary outcomes included clinical 
events and ambulatory ECG and exercise test findings. Clinical 
events included death, myocardial infarction, cardiac arrest, 
unstable angina, sustained ventricular tachycardia and conges- 
tive heart failure. Death and ischemic events were classified by 
an independent Mortality and Morbidity Classification Com- 
mittee using prespecified definitions and without knowledge of 
the treatment assignment. Other clinical outcomes recorded 
were the occurrence and severity of angina, new or repeat 
revascularization procedures and hospital admission for car- 
diovascular events. Ambulatory ECG findings, other than those 
at the 12-week visit, included frequency and duration of 
ischemia and frequency of sustained ventricular tachycardia 
(defined as consecutive ventricular depolarizations at a rate 
->100 beats/rain lasting ->30 s). Patients who died, experienced 
a myocardial infarction or had a nonprotocol revascularization 
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procedure were classified as having ischemia present on am- 
bulatory ECG recordings performed subsequent tothe event, 
regardless of actual ambulatory ECG findings. Exercise test 
findings included the presence of ischemic ST depression or 
angina, heart rate, work load, rate-pressure product (blood 
pressure × heart rate), duration of exercise at onset of ST 
segment depression, time to angina nd total duration of exercise. 
The ACIP study protocol was approved by institutional 
committees on human research at each participating center, 
and all patients provided written informed consent before 
entry into the study. An independent Data Safety and Moni- 
toring Board reviewed ata relative to secondary outcome as 
well as trial safe~ at 6-month intervals. 
Statistical methods. Data reported here are for 558 of the 
original 618 patients randomized inthe ACIP study. Data from 
one clinical center were recently found to be of unacceptable 
quality, so all 60 patients enrolled at that center have been 
excluded (14). However, the inclusion or exclusion of these 
patients does not change the results of analyses presented in
this report. 
In all analyses, patients were included in the group to which 
they were randomly assigned regardless of whether protocol 
treatment (pharmacologic therapy or revascularization) was 
actually received ("intention-to-treat analysis"). Data for 
patients assigned to the different pharmacologic treatments 
(atenolol-nifedipine or diltiazem-isosorbide dinitrate) were 
pooled for comparison of the three treatment strategies. 
Statistical analyses of categorical data were performed using 
the Fisher exact test or chi-square test, and continuous data 
were evaluated using analysis of variance. The Wilcoxon 
rank-sum statistic was used for testing the distribution of 
episodes of ischemia on the ambulatory ECG. The likelihood 
ratio test, with a logistic regression model adjusting for number 
of ischemic episodes on the qualifying ambulatory, ECG, was 
used for the global test of treatment differences of the 12- 
month visit ambulatory ECG outcome. 
The percent of patients with ischemic ST segment depres- 
sion during the initial 10 min of the exercise test was estimated 
using the Kaplan-Meier method (15). Patients not completing 
10 rain of exercise for reasons other than ST segment depres- 
sion were censored without he event at the time the test was 
stopped. This analytic method was also used to estimate the 
percent of patients with angina during the initial 10 rain of the 
exercise test. 
To account for the many hypotheses tested in the ACIP 
study, p = 0.01 was regarded as showing some evidence against 
the null hypothesis, and p = 0.001 was regarded as strong 
evidence for secondary, analyses. All of the analyses in this 
report, except quantitation fambulatory ECG ischemia t the 
12-week follow-up visit, are secondary analyses. The results 
presented in this study are based on data processed in the 
ACIP Clinical Coordinating Center as of January 18, 1995. 
Resu l ts  
Patients and treatment assignments. Baseline characteris- 
tics of the 558 enrolled patients are shown in Table 1. There 
were no significant differences in important baseline variables 
among the 183 patients assigned to the angina-guided strategy, 
the 183 patients assigned to the ischemia-guided strategy and 
the 192 patients assigned to the revascularization strategy. 
Details of revascularization are provided elsewhere (16). On 
final data edit, 7 of the 558 randomized patients were found in 
retrospect to have one of the following exclusion criteria at 
entry: myocardial infarction within the previous 4 weeks (n = 
2, angina-guided strategy); angioplasty within the previous 6 
months (n = 2, angina-guided strategy; n = 2, ischemia-guided 
strategy; n = 1, revascularization strategy). All of these pa- 
tients were included in the analyses. 
Medical therapy for all patients. Among patients assigned 
to the angina-guided and ischemia-guided strategies, 16% and 
15%, respectively, required no unblinded medication to con- 
trol angina at the 12-week follow-up visit. This proportion 
increased to 26% and 31%, respectively, at the 1-year visit, 
whereas the proportion of patients taking one or both study 
drugs decreased over follow-up (Fig. 2). At each visit (12 
weeks, 6 months and 1 year after entry), the proportion of 
patients receiving no, one, or two unblinded study medications, 
respectively, for angina treatment was similar between those 
assigned in blinded manner to the angina-guided versus 
ischemia-guided strategy, confirming that the blinding process 
was effective. Among patients assigned to the ischemia-guided 
strategy, the total number of medications provided was higher 
because both unblinded and blinded medications were "active" 
(Fig. 2, bottom right). Among patients assigned to revascular- 
ization, 63% required no unblinded medication for angina at 
the 12-week follow-up visit, and this proportion remained 
stable through the 1-year visit. 
The number of patients receiving active study drug was 
higher among patients assigned to either the ischemia-guided 
or the angina-guided strategy than to the revascularization 
strategy and diminished slightly from the 12-week visit to the 
1-year visit (Fig. 3). The daily dose of active study drug was 
much greater at the 12-week visit with the ischemia-guided 
strategy than with the other two strategies, and this difference 
persisted throughout 1-year follow-up. 
Clinical events. At 1 year after entry, follow-up was 100% 
complete for death and 96% complete for other clinical events. 
No patient experienced a nonfatal cardiac arrest or sustained 
ventricular tachycardia on ambulatory ECG monitoring. At 
one or more follow-up visits through the 1-year visit, stroke was 
reported in two (1.1%), one (0.5%) and no patients in the 
angina-guided, ischemia-guided and revascularization strategy 
groups, respectively (p = NS); congestive heart failure was 
recorded in two (1.1%), seven (3.8%) and five (2.6%) patients 
(p = NS); and unstable angina was recorded in eight (4.4%), 
five (2.7%) and three (1.6%) (p = NS). 
Hospital admissions through 1 year (365 days) after entry 
(other than for protocol revascularization) occurred in signif- 
icantly fewer patients assigned to the revascularization strategy 
than for each of the other two treatment s rategies (Fig. 4). 
Angioplasty (excluding protocol procedures) was performed in
16 patients (8.7%) in the angina-guided strategy group, 13 
(7.1%) in the ischemia-guided strategy group and 10 (5.2%) in 
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Table 1. Baseline Characteristics 
Angina Guided 
(n = 183) 
No. % 
Treatment Strategy 
Ischemia Guided Revascularization All 
(n = 183) (n = 192) (n = 558) 
No. % No. % No. % 
Age (yr) 61 ± 8 
->60 yr 111 
Male gender 164 
White 157 
Nonwhite 26 
Angina 
Within -<6 wk of entry 105 
On QV ETT or other stress test 90 
With ischemic episode on QV AECG 15 
Any of these 125 
History 
Previous MI 70 
Diabetes 21 
Heart failure 5 
Peripheral vascular disease* 5 
Hypertension 59 
Current smoker 35 
Ever smoked* 138 
Previous PTCA 37 
Previous CABG 9 
Previous PTCA or CABG, or both 45 
Physical examination 
Systolic pressure (mm Hg) 
Diastolic pressure (mm Hg) 
Heart rate (beats/min) 
Stenosis >-50% 
1 vessel 41 
2 vessels 66 
3 vessels 76 
Ejection fraction 
<35% 0 
35% to 49% 17 
50% to 64% 74 
>-65% 83 
Not available 9 
Rest 12-lead ECG 
Normal 105 
Q waves 19 
ST segment depression 40 
T wave abnormalities 50 
62 ± 8 61 ± 8 61 ± 8 
61 116 63 116 60 343 62 
90 156 85 159 83 479 86 
86 153 84 168 88 478 86 
14 30 16 24 12 80 14 
57 110 60 110 57 325 58 
49 105 57 105 55 300 54 
8 27 15 21 11 63 11 
68 131 72 135 70 391 70 
38 73 40 83 43 226 40 
11 35 19 34 18 90 16 
3 4 2 7 4 16 3 
3 25 14 8 4 38 7 
32 75 41 75 39 209 37 
19 31 17 24 13 90 16 
75 119 65 109 57 366 66 
20 32 18 31 16 100 18 
5 12 7 10 5 31 6 
25 41 22 40 21 126 23 
137 ± 18 141 2 21 139 ± 19 139 ± 20 
79 ± 10 80 ± 10 79 ± 10 79 ± 10 
69 ± 12 70 2 11 69 ± 12 69 ± 12 
22 45 25 50 26 136 24 
36 64 35 81 42 211 38 
42 74 40 61 32 211 38 
0 4 2 4 2 8 2 
10 18 10 16 9 51 10 
42 81 46 76 43 231 44 
48 75 42 82 46 240 45 
5 14 28 
57 89 49 93 48 287 51 
10 25 14 24 12 68 12 
22 48 26 44 23 132 24 
27 55 30 65 34 170 30 
*p = 0.001; otherwise no significant differences. Data presented are mean value + SD or number and percent of patients. AECG = ambulatory electrocardiogram; 
CABG = coronary artery bypass urgery; ETT = exercise test; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty; QV = qualifying 
visit. 
the revascularization strategy group (overall and pairwise 
comparisons, p = NS). Bypass surgery (excluding protocol 
procedures) was performed in 28 patients (15.3%) in the 
angina-guided strategy group, 36 (19.7%) in the ischemia- 
guided strategy group and 8 (4.2%) in the revascularization 
group (overall, p < 0.001; angina-guided versus ischemia- 
guided, p = NS; other pairwise comparisons, p < 0.001). 
Excluding protocol procedures, bypass surgery and the combi- 
nation of angioplasty or bypass surgery were performed more 
frequently in the angina-guided and ischemia-guided strategy 
groups than in the revascularization strategy group (Fig. 5). 
Reasons for revascularization differed among the three treat- 
ment arms (Fig. 6). Although the primary specified reasons for 
revascularization in each group were overt or exercise-induced 
ischemia and coronary anatomy, physician preference (reason 
unspecified) was much more commonly cited as the rationale 
for revascularization i patients assigned to either of the 
medical treatment strategies than for those assigned to the 
revascularization strategy. 
By 1 year after entry, myocardial infarction had occurred in 
10 patients (5.5%) in the angina-guided strategy group, 9 
(4.9%) in the ischemia-guided strategy group and 5 (2.6%) in 
the revascularization strategy group (overall and each pairwise 
comparison, p = NS). Death by 1 year after entry had occurred 
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F igure  2. Use of ACIP study medi- 
cation in the three treatment strate- 
gies at 12-week, 6-month and 1-year 
visits after randomization. Use of 
unblinded medication for control of 
anginal symptoms was similar in pa- 
tients assigned to the angina-guided 
and ischemia-guided strategies. Most 
patients assigned to the revascular- 
ization strategy required no medica- 
tion for anginal control. 
in eight patients (4.4cJk) in the angina-guided strategy group, 
three in the ischemia-guided strategy group (1.6%) and no 
patient in the revascularization strategy group (Fig. 7, top) 
(p = 0.004 by the Fisher exact test). Among 41 patients in the 
angina-guided strategy group who underwent revascularization 
within the next year, myocardial infarction occurred in 2 and 
death in 2 after the procedure. Similarly. among 47 patients in 
the ischemia-guided group who subsequently underwent revas- 
cularization, myocardial infarction and death occurred in 3 and 
1, respectively, after the procedure. 
Mortality in patients assigned to the revascularization strat- 
egy was significantly less common than in those assigned to the 
angina-guided strategy (p = 0.003) but was similar to those 
assigned to the ischemia-guided strategy (p = 0.12, Fisher 
exact test). Similarly, the combined incidence of death or 
myocardial infarction was less common in patients assigned to 
Dai ly  Dose  o f  S tudy  Drug  (mg)  
300 - t 
/ 
25O 
200 - -  - -  ~i - - -  
1 go 62 ~ii:: 
:::::::: .:~ = :~ 
50  56 _ I schemia  Gu ided  
Angina Guided 
i 
0 D A I N D A I N D A I N D A I N Revascularization 
12 Wk 6 Mo 9 Mo 12 Mo 
Number 81 82 46 48 71 72 38 41 70 70 35 38 64 65 29 37 Isehemia Guided  
Pts On 
Study 78 71 28 16 68 64 22 16 63 66 2t 18 61 62 21 20 Angina Guided 
Meds 29 37 10 7 34 43 10 10 30 42 10 10 28 40 10 11 Revascularization 
F igure  3. Quantity of ACIP study 
medication used in each treatment 
strategy. More patients assigned to 
the ischemia-guided strategy re- 
ceived ACIP study medication at 
each follow-up interval, and their 
average daily dose of each medica- 
tion was also higher than patients 
assigned to each of the other treat- 
ment strategies. A = atenolol; D = 
diltiazem; I = isosorbide dinitrate; 
Meds - medications; N = nifedi- 
pine; Pts = patients. 
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Figure 4. Percent of patients admitted to the hospital for 
other than protocol-assigned procedures. Significantly fewer 
patients assigned torevascularization were admitted to the 
hospital during the 1-year follow-up. 
% with Hospitalization 
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18% 
the revascularization strategy than the angina-guided, but not 
the ischemia-guided, strategy (Fig. 7, bottom). The incidence 
of either death, myocardial infarction, nonprotocol revascular- 
ization or hospital admission was less common with revascu- 
larization than with either of the two medical strategies (Fig. 
8). The frequency of hospital admission, myocardial infarction, 
death, revascularization r the combined events was not dif- 
ferent between the angina-guided and the ischemia-guided 
strategies. 
Ambulatory ECG findings. Ambulatory ECG results (from 
>36-h recordings) were available for 96% of patients at the 
baseline qualifying visit, 85% at the 12-week visit, 87% at the 
6-month visit and 88% at the 12-month visit. The number and 
length of ischernic episodes among treatment s rategies were 
similar throughout follow-up, but heart rate at the time of the 
ischemic episodes tended to be higher in patients assigned to 
the revascularization strategy group (Table 2). 
Complete suppression of ischemia on the 48-h ambulatory 
ECG was achieved in a higher proportion of patients assigned 
to the revascularization strategy group at the visits scheduled 
for 12 weeks, 6 months and 1 year after entry (Fig. 9). 
However, by the 1-year visit, 28% of the patients in both the 
angina-guided and ischemia-guided arms were counted as 
having ischemia related to an interim event (myocardial infarc- 
tion, death or nonprotocol revascularization) rather than to 
the actual ambulatory ECG findings, compared to 11% of the 
patients in the revascularization arm (p < 0.001). When only 
myocardial infarction and death are counted as surrogates for 
ischemia on the ambulatory ECG, the proportion of patients 
without ischemia t the i-year visit was 42% in the angina- 
guided strategy group, 50% in the ischemia-guided strategy 
group and 60% in the revascularization strategy group (overall, 
p --- 0.004; angina-guided vs. revascularization, p = 0.001; 
other pairwise comparisons, p = NS). 
Exercise test findings. Exercise test results were available 
for 98% of patients at the baseline qualifying visit, 90% at the 
12-week visit, 88% at the 6-month visit and 87% at the l-year 
visit. Patients assigned to the revascularization strategy exercised 
to a higher ate-pressure product, achieved a higher percent of 
age-predicted maximal heart rate and less often experienced 
angina on exercise than patients assigned to the other two 
strategies (Table 3). Finally, in the revascularization group, the 
proportion of patients with ~l-mm ST segment depression 
tended to be lower, the time and rate-pressure product for 
Figure 5. Percent of patients undergoing onprotocol-assigned 
revascularization. More nonprotocol-assigned angioplasty 
(PTCA) or bypass surgery (CABG) was performed in patients 
assigned to the angina-guided or ischemia-guided strategies 
than in those assigned tothe revascularization strategy. 
% with PTCA or CABG (excluding protocol procedures) 
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Figure 6. Reasons for performing nonprotocol-assigned 
angioplasty (PTCA, left) or bypass surgery (CABG, right) 
during the year after randomization. Because multiple 
reasons could be indicated, a hierarchy was created so that 
only the first of the following five reasons listed would be 
considered: 1) ischemia (including myocardial infarction, 
unstable angina, or Canadian Cardiovascular Society class 
III or IV angina [23]); 2) coronary anatomy or a severe 
ischemic ECG response on treadmill exercise t sting (Anat/ 
ETT); 3) failed angioplasty; 4) physician preference-- 
reason ot specified; and 5) other. Reasons are shown for 
the first bypass urgery or first angioplasty procedure, or
both, for each patient. The overall frequency of nonprotocol 
angioplasty was not significantly different among the three 
strategies, but nonprotocol bypass urgery differed signifi- 
cantly (p < 0.001 overall; p < 0.001 for pairwise compari- 
sons of each medical strategy vs. revascularization strategy). 
Physician preference was more often a reason for revascu- 
larization i  the angina-guided (AG) and ischemia-guided 
(IG) groups than in the revascularization group (Rev). 
1-mm ST segment depression tended to be greater, and the 
extent of ECG abnormality ended to be less (Table 3). 
Discussion 
Comparison of 1-year with 12-week outcome. One-year 
follow-up of patients randomized in the ACIP study extends 
the findings previously noted at 12 weeks after randomization 
(13). Patients assigned to the ischemia-guided strategy were 
provided more protocol medication than those assigned to the 
angina-guided strategy, but the extent of ischemia on the 
ambulatory ECG and exercise test was generally similar, as 
were rates for death, combined eath and myocardial infarc- 
tion, hospital admission and nonprotocol revascularization. 
Patients assigned to revascularization required significantly 
less antianginal medication during follow-up than either of the 
other two groups, experienced less asymptomatic ischemia on 
ambulatory ECG recordings and less often had angina or ST 
segment depression on treadmill exercise testing. However, 
unlike the findings at 12 weeks, 1-year follow-up demonstrated 
significant trends in clinical outcome favoring patients assigned 
to revascularization. These trends included mortality, com- 
bined death and myocardial infarction, hospital admission and 
frequency of nonprotocol revascularization. 
Comparison with previous studies. Although treatment of
asymptomatic ischemia by either medication or revasculariza- 
tion has been described (8-10), many of the previous eries 
have been limited by relatively small numbers of subjects, hort 
duration of follow-up, lack of angiographic documentation f 
coronary artery disease and varying definitions of asymptom- 
atic ischemia by exercise testing and ambulatory ECG record- 
ing. Although controlled trials of pharmacologic therapy for 
asymptomatic cardiac ischemia have recently been performed 
(17-20), to our knowledge there have been no previous 
controlled studies comparing pharmacologic therapy with re- 
vascularization. 
The ACIP study demonstrates that the extent of suppres- 
sion of ambulatory ECG ischemia with either medical therapy 
or revascularization is relatively stable over 1-year follow-up 
(Table 2) despite a decreasing usage of protocol-specified 
medication at each follow-up interval (Fig. 2 and 3). Surpris- 
ingly, ischemia was not suppressed more completely with the 
ischemia-guided strategy despite a much higher dosage of 
pharmacologic therapy (Fig. 3). The revascularization strategy 
allowed freedom from antianginal medication i most patients 
and appeared to be far superior to either the angina-guided or
ischemia-guided strategy insuppressing both ambulatory ECG 
and exercise test evidence of ischemia. Although each of the 
three treatment s rategies was partially effective in suppressing 
ischemia over the 1-year observation period, >40% of patients 
with each strategy had persistent evidence of ischemia on 
ambulatory ECG recordings, imilar to previous observations 
by Deedwania nd Carbajal (5). In a subgroup analysis from 
the ACIP study, Bourassa et al. (16) found that bypass urgery 
was more effective in suppressing ischemia than angioplasty, 
probably as a result of more complete revascularization. Thus, 
to our knowledge the ACIP study is the first to suggest that 
clinical outcome (death, death/myocardial infarction, hospital 
admission and revascularization) is improved in patients with 
asymptomatic cardiac ischemia initially treated with revascu- 
larization rather than pharmacologic therapy (Figs. 4, 5, 7 and 8). 
Event rates in the ACIP study. One of the primary objec- 
tives of the ACIP study was to ascertain rates of death and 
myocardial infarction to establish whether a large-scale trial 
with clinical rather than ambulatory ECG end points would be 
feasible. In the ACIP patients, the incidence of death with 
angina-guided therapy at l-year follow-up was 4.4%, and the 
incidence of death or myocardial infarction was 8.8%. These 
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Figure 7. Death and myocardial infarction. Although the 
number of fatal events was small, the percent of patients 
who died during the 1-year follow-up was significantly lower 
for patients assigned to the revascularization strategy than 
for those assigned to the angina-guided strategy, but not for 
those assigned to the ischemia-guided strategy (top). The 
mortality rate was similar between the angina-guided and 
ischemia-guided strategies. The combination of death or 
myocardial infarction was significantly less common among 
patients assigned to the revascularization strategy than 
among those assigned to the angina-guided but not the 
ischemia-guided strategy (bottom). 
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rates are similar to those for death (>1.5% to 3.7%) and 
combined eath and myocardial infarction (1.3% to 13.6%) 
noted in a recent summary of previous observational studies of 
patients with stable coronary artery disease and ambulatory. 
ECG-detected ischemia who were followed up for 6 to 36 
months (21). 
If a large-scale trial, similar in design to the ACIP study, 
were performed to assess the impact of treatment of asymp- 
Figure 8. Death, myocardial infarction (M1), nonprotocol 
angioplasty (PTCA) or bypass surgery (CABG) or hospital 
admission. This composite secondary outcome was signifi- 
cantly less common among patients assigned to the revascu- 
larization strategy, than among those assigned to the other 
two treatment strategies. 
% with Death, MI, Non-protocol PTCA/CABG or Hospital ization 
35 
30 
25 
20 
15 
10 
5 
0 
Overall." p = .003 
Angina Guided vs Ischemia Guided: p NS 
Angina Guided vs Revascularization: p = .002 
Ischemia Guided vs Revasculafization: p = .004 
Angina Gu lded .~,0 .  ,° •°L .~. ° Ischemia Guided 
t Revasculanzation 
0 90 180 270 360 
Days after Randomization 
32% 
31% 
18% 
602 ROGERS ET AL  JACC Vol. 26, No. 3 
ONE-YEAR OUTCOME IN ACIP September 1995:594-605 
E 
[.. 
;:> 
,,.-, 
.,...., 
._o 
L" 
o 
r~ 
<: 
,.-,i 
m 
¢ 
i 
eq 
;2, 
O' 
>- 
oc  
II 
II 
oc 
I I  
II 
,'¢ = 
'v '  
VVV 
V V V 
_ ~, -  _ =d ~- = _= 
_~A ~, . ,qs .~_  -~  ,--~~. ~. _@ ,~=_ ~ 
r ,4  , -~ 
oc  
~=~ ~, Z = Z ~ = ~  ~ -- -~E ~ I 
r,, ~ ~~'~-~ ~ ~ ~ ~ ~d ~'Z~ ~"~ o . . . .  
o 
~Z 
E ..;-_* 
g 
• ~ ,'0 
o4  ~ ~ 
8 
v.~ >~ 
~5 
JACC Vol. 26, No. 3 ROGERS ET AL. 603 
September 1995:594-605 ONE-YEAR OUTCOME IN ACIP 
% with No Ischemia on AECG 
70 tl • Angina-Guided 
60 Ii 57 Ischemia-Guided 54 55 
50 [~_ Re_vasc_ularizalian 
401 ill 30 2o [ 
10 
o o 0 o ~N~ I 
Qualifying Visit 12 wk 6 mo 1 yr 
Figure 9. Percent of patients free of ischemia on the ambulatory 
electrocardiogram (AECG). By definition, all patients had one or 
more episodes of asymptomatic ischemia on 48-h ambulatory ECG 
monitoring at the baseline qualifying visit. At 12-week (primary 
outcome), 6-month and 1 year follow-up, ischemia on the ambulatory 
ECG was suppressed in each of the three treatment groups but was 
more often completely suppressed in patients assigned torevascular- 
ization (overall comparison a d pairwise comparisons of revascular- 
ization strategy vs. each of the other two arms, p < 0.001 at each 
follow-up interval; angina-guided vs. ischemia guided strategy, p = NS 
at each follow-up interval). 
tomatic ischemia on the combined end point of death plus 
myocardial infarction, it is estimated that a total sample size 
of 5,300 patients would be needed for a study of three 
treatment strategies to ensure at least an 85% power for 
detecting a difference in the primary end point for any 
two-group comparison at alpha 0.05 (22). This estimate 
assumes a conservative 5-year event rate (death and myo- 
cardial infarction combined) of 22.5% for the angina-guided 
(usual) strategy. 
Need for a large-scale trial of medical therapy versus revas- 
cularization for asymptomatic ischemia. Despite its relatively 
small sample size, the AC1P study unexpectedly showed a 
statistically significant advantage of revascularization over 
medical therapy for a number of clinical end points at 1-year 
follow-up. Are the ACIP data, therefore, conclusive in estab- 
lishing the superiority of revascularization ver medical ther- 
apy for the control of asymptomatic ischemia? 
Several caveats hould be considered. 1) Although cur- 
rently the largest reported study of comparative strategies 
for asymptomatic schemia, the ACIP study is itself a 
relatively small trial, and its 1-year follow-up eriod is a very 
short time interval for accurately assessing the results of 
therapy of ischemic heart disease. 2) The number of deaths 
recorded during 1-year follow-up (eight with the angina- 
guided strategy, three with the ischemia-guided strategy and 
none with the revascularization strategy) is, overall, signif- 
icantly different in favor of revascularization, but the num- 
ber of deaths is not significantly different between the 
ischemia-guided strategy and the revascularization strategy. 
That no deaths occurred in the revascularization group after 
1-year follow-up seems unusual. Obviously, the statistical 
comparison among the three groups is somewhat "unstable" 
because overall significance would be lost if there were only 
one reported eath with the revascularization strategy. 3) 
The frequency of other clinical events (myocardial infarc- 
tion, unstable angina, stroke and congestive heart failure) 
was not significantly different among the three treatments. 
4) Revascularization, performed by physician preference 
rather than for protocol-specified reasons, was more com- 
mon in the patients assigned to the angina-guided and 
ischemia-guided strategies and most likely indicated bias 
toward the revascularization arm, which could not be 
blinded. Although these revascularizations i  patients as- 
signed to the medical strategies tend to increase the simi- 
larity of the three treatment arms, theoretically making it 
more difficult to demonstrate differences in outcome among 
the treatments, they also inflate the frequency of adverse 
outcomes by increasing the number of hospital admissions 
and revascularization procedures. Furthermore, by proto- 
col, these revascularizations require subsequent ambulatory 
ECG recordings to be imputed as "positive" for ischemia, 
regardless of whether ischemia was actually present. Thus, 
the superior suppression ofambulatory ECG ischemia in the 
revascularization strategy at 1 year can be accounted for, in 
part, by revascularization procedures performed in the other 
two strategies for physician preference rather than ischemia. 
5) Although more medication was provided to patients in 
the ischemia-guided strategy group, it may not have been 
titrated to its highest possible (and perhaps most effective) 
level during the initial 12 weeks, and there was no provision 
to continue upward titration of blinded medication after the 
first 12 weeks after randomization. 
These limitations imply that although the ACIP study was a 
successful pilot study demonstrating that patients satisfying the 
study criteria could be effectively recruited and randomized to
various treatments for asymptomatic is hemia, a larger scale 
trial with a more prolonged ose-titration phase and a longer 
duration of follow-up would be needed to definitively compare 
medication with revascularization for the treatment of asymp- 
tomatic myocardial ischemia. 
Clinical implications. One-year follow-up of patients with 
asymptomatic ischemia randomized to an angina-guided 
strategy, an ischemia-guided strategy and a revasculariza- 
tion strategy in the ACIP study demonstrates a low fre- 
quency of events, averaging 2.0% for death and 4.3% for 
myocardial infarction. Revascularization appears uperior 
to both angina-guided and ischemia-guided therapy for 
suppression of ischemia on the ambulatory ECG and the 
exercise test. These pilot data also suggest that survival of 
patients with asymptomatic ischemia may be prolonged by 
revascularization, but a larger scale trial with a longer 
follow-up duration is needed for confirmation. 
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Appendix 
Participating Clinical Units, Core Laboratories and 
Clinical Coordinating Center for the ACIP Study 
ACIP Clinical Units. University of Alabama at Birmingham: W. J. Rogers, 
MD,* K. A1-Shaibi, MD, V. A. Bittner, MD, D. A. Cox, MD, K. Z. Hanna, MD, 
M. A. Lawson, MD, R. L, Levine, MD, T. Paine, MD, J. M. Parks, MD, D. J. 
Pearce, MD, H. Taylor, MD, V. K. Varma, MD, G. H. Duke, LPN, L, Levson, 
RN, L. Maske, RN, L. McDaniel, RN, J. Moody, RN, T. Morgan, RN, F. Atkins, 
S. Brewer, K. Doss, D. Bunn. Baylor College of Medicine: C. M. Pratt, MI,* 
G. Habib, MD, N. Kleiman, MD, J. Mahmarian, MD, R. Roberts, MD, B. Stein, 
MD, M. Francis, RN, T. Hollo, L. Miller, G. Morris, RN, R. Rodriquez, RN, 
C. Thibodeaux. University of Florida and VAMC Gainesville: C. J. Pepine, MD, '~ 
J. A. Alexander, MD, B. Bertolet, MD, J. Hill, MD, M. Limacher, MD, 
M. Staples, MD, T. Wargovich, MD, E. Handberg, RN, MSN, H. R. Kolb, RN, 
A. Boyette, G. K. Ruby, RN. Henry Ford Hospitak A. D. Goldberg, MD,* 
S. Goldstein, MD, L. Dvorak, RN, C. Knight, RN, D. Frank, RN, D. Strother, 
RN. Johns Hopkins University: P. Ouyang, MD,* R. S. Blumenthal, MD, S. O. 
Gottlieb, MD, M. Kelemen, MD, S. P. Schulman, MD, H. Lutz, RN, 
S. N. Townsend, RN. Albert Einstein College of Medicine: H. Mueller, MD,* 
J. Catanese, MD, R. Frater, MD, W. Frishman, MD, A. Gambino, MD, 
M. Gentilucci, MD, M. H. Goldberger, MD, M. A. Greenberg, MD, H. Hirsch, 
MD, A. Landau, MD, R. Moisa, MD, E. S. Monrad, MD, R. M. Steingart, MD, 
M. E. Coglianese, RN, J. Cosico, RN, M. Fornasier-Bongo, BS, S. Furia, RN, 
K. Hemingway, RN. Montreal Heart Institute: M. G. Bourassa, MD,* R. Bonan, 
MD, I. Dyrda, MD, J. Lesp6rance, MD, Y. LeClerc, MD, C. Pelletier, MD, 
C. Faille, A. M. Poitras, RN, J. Trudel, RN. University of Ottawa Heart Institute. 
R. F. Davies, MD,* M. Baird, MD, D. Beanlands, MD, R. Masters, MD, 
L. Higginson, MD, J. F, Marquis, MD, T. Ruddy, MD, L. Laramee, MD, 
M. LeMay, MD, A. Baker, RN, M. Fraser, RN, S. Grichen, RN. St. Bar- 
tholomew's Hospital, London, U.K.: J. E. Deanfield, MD,* D. Dymond, MD, 
R. Lira, MD, J. Elstob, RN. Saint Louis University Medical Center and VAMC: 
B. R. Chaitman, MD,* G. Williams, MD, F. Aguirre, MD, P. Bjerregaard, MD, 
E. Caracciolo, MD, G. Kaiser, MD, M. Kern, MD, L. McBride, MD, D. D. Miller, 
MD, H. G. Stratmann, MD, R. D. Wiens, MD, S. Byers, RN, P. Flynn, RN. 
ACIP Central Units.ACIP Study Chairman: C. R. Conti, MD, University of 
Florida, Gainesville. Clinical Coordinating Center. Maryland Medical Research 
Institute: G. L. Knatterud, PhD,* M. L. Terrin, MD, MPH, S. Forman, MA, 
R. McMahon, PhD, E. Mirenzi, R. Giro, M. Carroll, C. Kelly, L. Monroe, 
P. Noble, J. Dotson. Ambulatory ECG Core Laboratory: Brigham and Women's 
Hospital: P. Stone, MD,* T. Andrews, MD, G. MacCallum, M. Smalls. Rest and 
Exercise ECG Core Laboratory: St. Louis University: B. Chaitman, MD,* 
I. Gussak, MD, K. Zumbehl, BS, D. Kargl, BS, K. Stocke, BS, MBA. Angio- 
graphic Core Laboratory: Brown University: B. Sharaf, MD,* G. R. McKendafi, 
MD, R. S. Riley, MD, E. S. Thomas, MD, D. O. Williams, MD, N. Miele, BA, 
P. E. Ferreira, RN. Research Pharmacy Coordinating Center." P. Day, RPh, MS* 
(until April 1993), N. Morgan, RPh, MBA* (April 1993), M. Sather, MS, 
FASHP, J. Overfe[t, J. Price, C. Tripp, S. Mallory. Project Office, Cardiac Diseases 
Branch, Division of Heart and Vascular Diseases and Biostatistics Research Branch, 
Division of Epidemiology and Clinical Applications, National Heart, Lung, and 
Blood Institute: G. Sopko, MD, MPh* (ACIP Project Officer), M. Horan, MD, 
N. Geller, PhD, M. Prosehan, PhD, K. Camilletti, D. Frye, S. Kraft. 
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